Which companies are affected by this news?

Companies directly affected include: PARK, PHAT.

Which industries does this news affect?

AlphaOS tracks industry-level impact for all major market events.

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Q: What is the market impact of: Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)?

AlphaOS is tracking this market event: Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE).

July 10, 2026 · 2 sources · Updated Jul 10, 2026

Affected Companies

PARK

Park Dental Partners, Inc.

$21.00$94.82M cap

PHAT41

Phathom Pharmaceuticals, Inc.

$12.60$1.00B cap

AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.